# Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients

> **NCT03141203** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Birmingham** · enrollment: 50 (actual)

## Conditions studied

- Peripheral T Cell Lymphoma

## Interventions

- **DRUG:** Romidepsin
- **DRUG:** Carfilzomib

## Key facts

- **NCT ID:** NCT03141203
- **Lead sponsor:** University of Birmingham
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-13
- **Primary completion:** 2020-08
- **Final completion:** 2021-09-23
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2022-05-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03141203

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03141203, "Evaluation of the Combination of Romidepsin and Carfilzomib in Relapsed/Refractory Peripheral T Cell Lymphoma Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03141203. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*